

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

**CHANGE OF NON-EXECUTIVE DIRECTOR
AND
APPOINTMENT OF EXECUTIVE DIRECTOR
AND MEMBER OF THE EXECUTIVE COMMITTEE
AND
CHANGE OF MEMBERS OF AUDIT COMMITTEE AND REMUNERATION AND
APPRAISAL COMMITTEE**

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) hereby announces that, with effect from 27 December 2023, (1) Mr. Lin Guolong (“**Mr. Lin**”) has resigned as a non-executive Director, a member of the audit committee of the Company (“**Audit Committee**”) and a member of the remuneration and appraisal committee of the Company (“**Remuneration Committee**”); (2) Mdm. Deng Rong (“**Mdm. Deng**”) has been appointed as an executive Director and a member of the executive committee of the Company (the “**Executive Committee**”); (3) Mr. Sun Yongqiang (“**Mr. Sun**”) has been appointed as a non-executive Director and a member of the Remuneration Committee; and (4) Mdm. Guo Wei (“**Mdm. Guo**”) has been appointed as a member of the Audit Committee.

RESIGNATION OF A NON-EXECUTIVE DIRECTOR, A MEMBER OF THE AUDIT COMMITTEE AND A MEMBER OF THE REMUNERATION COMMITTEE

Mr. Lin has resigned as a non-executive Director, a member of the Audit Committee and a member of the Remuneration Committee with effect from 27 December 2023 due to his other work arrangements. Mr. Lin has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the holders of securities of the Company.

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Lin for his invaluable contributions to the Group and the Board.

APPOINTMENT OF AN EXECUTIVE DIRECTOR AND A MEMBER OF THE EXECUTIVE COMMITTEE

Mdm. Deng Rong, aged 45, has been appointed as the chief financial officer of the Company in June 2023, and has been appointed as an executive Director and a member of the Executive Committee on 27 December 2023, and she is currently the director of certain subsidiaries of the Company, a director of Jiangzhong Pharmaceutical Co., Ltd. (江中藥業股份有限公司) (a subsidiary of the Company listed on the Shanghai Stock Exchange, stock code: 600750.SH), also a director of Dong-E-E-Jiao Co., Ltd. (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”, a subsidiary of the Company, which is

listed on the Shenzhen Stock Exchange, Stock Code: 000423.SZ) and a supervisor of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司) (a subsidiary of the Company, which is listed on the Shenzhen Stock Exchange, Stock Code: 000999.SZ). She previously held various positions within China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) (“**CR Double-Crane**”, a subsidiary of the Company, which is listed on the Shanghai Stock Exchange, Stock Code: 600062.SH) from 2004 to 2020, including the Head of Financial Accounting and Tax Management Department at the Financial Management Center, General Manager of the Accounting Management Department at the Financial Management Center, General Manager of the CR Double-Crane Financial Management Center, General Manager of the Financial Shared Services Center, Director of Accounting Management, General Manager of the Business Financial Management Department, and General Manager of the Financial Functional Management Department. She has also served as Vice President, Board Secretary, and Chief Financial Officer at Dong-E-E-Jiao from 2020 to 2023. Mdm. Deng holds a Bachelor's degree in Accounting from Central South University (中南大學) and a Master's degree in Management from Beijing Jiaotong University (北京交通大學). She is a certified board secretary recognized by the Shenzhen Stock Exchange.

Under the service contract with the Company, Mdm. Deng has no fixed term of service with the Company but will be subject to rotational retirement and re-election requirements at annual general meetings of the Company at least once every three years pursuant to the articles of association of the Company.

The emoluments payable to Mdm. Deng are determined by the Board under the authority granted by the shareholders of the Company at annual general meeting and with reference to the recommendation made by the Remuneration Committee, her duties and responsibilities with the Company, the Company's performance and market situation. Mdm. Deng will not receive director's fee from the Company. She is entitled to pre-tax basic monthly salary of RMB70,100 from the Company based on her position, duties and responsibilities, as well as discretionary bonus and term-wide incentives based on the results performance of the Company and herself.

As at the date of this announcement, Mdm. Deng does not have any interests in the shares of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed above, Mdm. Deng has confirmed that (i) she has and had no other relationships with any directors, senior management or substantial or controlling shareholders of the Company; (ii) she does not currently hold any other position with the Company or any of its subsidiaries; (iii) she has not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) there are no other matters relating to the aforesaid appointment that need to be brought to the attention of holders of securities of the Company; and (v) there is no other information relating to the aforesaid appointment to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

Upon Mdm. Deng's appointment as a member of the Executive Committee, the requirement on number of members of the Executive Committee pursuant to its written terms of reference has been fulfilled.

APPOINTMENT OF A NON-EXECUTIVE DIRECTOR AND A MEMBER OF THE REMUNERATION COMMITTEE

Mr. Sun Yongqiang, aged 53, has been appointed as a non-executive Director and a member of the Remuneration Committee on 27 December 2023. He currently serves as a designated external director of business units of China Resources (Holdings) Company Limited. Mr. Sun joined China Resources Group in March 2001. From 2011 to 2023, he successively served as vice president, chief human resources officer and human resources director of China Resources Land Limited (“**CR Land**” , which is listed on the Main Board of the Stock Exchange, Stock Code: 1109), and also served as General manager and deputy general manager of China Resources Land (Hunan) Co., Ltd (華潤置地 (湖南)有限公司, a subsidiary of CR Land). Mr. Sun holds a Bachelor's Degree in Engineering from Dalian University of Technology (大連理工大學).

There is no service contract entered into between Mr. Sun and the Company for his position as a non-executive Director. Mr. Sun shall hold office until the next general meeting of the Company after his appointment and shall then be eligible for re-election at such meeting. Thereafter, Mr. Sun shall be subject to retirement by rotation at least once every three years at the annual general meeting pursuant to the articles of association of the Company. Mr. Sun will not receive any director's emolument from the Company.

As at the date of this announcement, Mr. Sun beneficially owned 70,000 shares of China Resources Beer (Holdings) Company Limited (an associated corporation of the Company and listed on the Main Board of the Stock Exchange, Stock Code: 291), 30,000 shares of CR Land (an associated corporation of the Company), 50,000 shares of China Resources Mixc Lifestyle Services Limited (an associated corporation of the Company and listed on the Main Board of the Stock Exchange, Stock Code: 1209), and 92,000 shares of China Resources Medical Holdings Company Limited (an associated corporation of the Company and listed on the Main Board of the Stock Exchange, Stock Code: 1515). Save as disclosed above, Mr. Sun does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Sun have confirmed that (i) he has and had no other relationships with any directors, senior management or substantial or controlling shareholders of the Company; (ii) he does not currently hold any other position with the Company or any of its subsidiaries; (iii) he has not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) there are no other matters relating to the aforesaid appointment that need to be brought to the attention of holders of securities of the Company; and (v) there is no other information relating to the aforesaid appointment to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

APPOINTMENT OF MEMBER OF THE AUDIT COMMITTEE

Mdm. Guo, a non-executive Director, has been appointed as a member of the Audit Committee on 27 December 2023.

The Board takes this opportunity to extend a warm welcome to Mdm. Deng, Mr. Sun and Mdm. Guo for the appointment.

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Beijing, 27 December 2023

As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.